Shares in stockbroker Cenkos Securities (CNKS) are currently up to around 40p, though down from more than 46p at the end of last week. This following a Monday intra-day (3:02pm) “Directorate Change & Trading Update”…
The crucial fundamental question for skins is how large the Revenue from Croda will be and much more significantly the timing of those revenues.If we assume that substantial Revenue from Croda will be received in the year ending 30 June 2028 the valuation looks very stretched.Just think how many shares would have to be raised to cover plc costs to provide working capital for one two or three years.I have no axe to grind I am just doing the maths.Toyin has a very detailed grasp of the product and maybe feels substantial revenue being generated is much closer.
Good listen, thank you for the podcast. Tom, I was wondering whether you have an opinion on Medpal AI after yesterday's announcement of a conditional £5 million fundraise at 5p and the subsequent price action. This would be the 5th fundraise in 10 months (4 placings this year and an ATM death spiral in November 2025). Despite the conditional placing being at 5p, I noticed that the lowest the shares went yesterday was 5.3p, before being aggressively bid up to 6.3p today, so I am not sure whether you have an opinion on what is going on?
No, they will have at least 12 months cash at sign off and FY27 ahead of management expectations, post presentation comments, which makes material uncert highly unlikely.
NOBODY is saying accounts will not be on a going concern basiswhat Sohail, myself and others we are saying is that auditors v likely to flag up material uncertainty
RNS dated 29 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, will be presenting to shareholders at 09.00 BST today, Monday 29 June 2026 on the Investor Meet Company platform (see details below). The presentation will be led by Alyson Levett, Acting Chair and Rachel Parsonage, Interim CEO.The presentation will be brief and cover recent post period events, the investigation and the disclosable information from the FRP Advisory report, before running through the recent HY26 results, post period trading and outlook. The Company will also be stating that the FY26 results will be prepared on a going concern basis.
Spot on! As U would expect from you.The auditors do not need to think there has to be a placing just that there might have to be to post material uncertainty. In the current climate they'd be insane not to do so